Table 4 Stage distribution and treatment rate for positive cases screened from the cohort
Site | Variable | N (%) | High-risk areas | Non-high-risk areas | P value |
|---|---|---|---|---|---|
N (%) | N (%) | ||||
All (n = 528) | Stage | < 0.001 | |||
 0 | 258 (48.9) | 247 (51.7) | 11 (22.0) | ||
 I | 178 (33.7) | 169 (35.3) | 9 (18.0) | ||
 II | 46 (8.7) | 32 (6.7) | 14 (28.0) | ||
 III/IV | 46 (8.7) | 30 (6.3) | 16 (32.0) | ||
Early-stagea | < 0.001 | ||||
 No | 92 (17.4) | 62 (13.0) | 30 (60.0) | ||
 Yes | 436 (82.6) | 416 (87.0) | 20 (40.0) | ||
Treatment | 0.511 | ||||
 No | 103 (19.5) | 95 (19.9) | 8 (16.0) | ||
 Yes | 425 (80.5) | 383 (80.1) | 42 (84.0) | ||
Esophagus (n = 254) | Stage | < 0.001 | |||
 0 | 166 (65.4) | 160 (67.0) | 6(40.1) | ||
 I | 64 (25.2) | 62 (25.9) | 2(13.3) | ||
 II | 17 (6.6) | 12 (5.0) | 5(33.3) | ||
 III/IV | 7 (2.8) | 5 (2.1) | 2(13.3) | ||
Early-stagea |  < 0.001 | ||||
 No | 24 (9.4) | 17 (7.1) | 7 (46.7) | ||
 Yes | 230 (90.6) | 222 (92.9) | 8 (53.3) | ||
Treatment | 0.271 | ||||
 No | 44 (17.3) | 42 (17.6) | 2(13.3) | ||
 Yes | 210 (82.7) | 197 (82.4) | 13(86.7) | ||
Stomach (n = 284) | Stage |  < 0.001 | |||
 0 | 96 (33.8) | 91 (36.7) | 5 (13.9) | ||
 I | 118 (41.6) | 111 (44.7) | 7 (19.4) | ||
 II | 31 (10.9) | 21 (8.5) | 10 (27.8) | ||
 III/IV | 39 (13.7) | 25 (10.1) | 14 (38.9) | ||
Early-stagea |  < 0.001 | ||||
 No | 70 (24.6) | 46 (18.5) | 24 (66.7) | ||
 Yes | 214 (75.4) | 202(81.5) | 12 (33.3) | ||
Treatment | 0.452 | ||||
 No | 61 (21.5) | 55 (22.2) | 6 (16.7) | ||
 Yes | 223 (78.5) | 193 (77.8) | 30 (83.3) | ||